Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Change in Receivables (2017 - 2025)

Sutro Biopharma's Change in Receivables history spans 9 years, with the latest figure at -$4.1 million for Q3 2025.

  • For Q3 2025, Change in Receivables fell 1282.03% year-over-year to -$4.1 million; the TTM value through Sep 2025 reached -$2.7 million, up 72.59%, while the annual FY2024 figure was -$27.5 million, 194.84% down from the prior year.
  • Change in Receivables for Q3 2025 was -$4.1 million at Sutro Biopharma, up from -$5.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $86.0 million in Q2 2022 and bottomed at -$86.4 million in Q3 2022.
  • The 5-year median for Change in Receivables is $126000.0 (2023), against an average of -$86631.6.
  • The largest annual shift saw Change in Receivables skyrocketed 4348.27% in 2022 before it tumbled 19425.4% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $124000.0 in 2021, then plummeted by 3429.03% to -$4.1 million in 2022, then soared by 571.2% to $19.5 million in 2023, then tumbled by 89.92% to $2.0 million in 2024, then tumbled by 307.9% to -$4.1 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Change in Receivables are -$4.1 million (Q3 2025), -$5.6 million (Q2 2025), and $4.9 million (Q1 2025).